Encephalitis Clinical Trials

48 recruitingLast updated: May 21, 2026

There are 48 actively recruiting encephalitis clinical trials across 30 countries. Studies span Phase 2, Not Applicable, Early Phase 1, Phase 1, Phase 3. Top locations include Paris, France, Wuhan, Hubei, China, Philadelphia, Pennsylvania, United States. Updated daily from ClinicalTrials.gov.


Encephalitis Trials at a Glance

48 actively recruiting trials for encephalitis are listed on ClinicalTrialsFinder across 6 cities in 30 countries. The largest study group is Phase 2 with 13 trials, with the heaviest enrollment activity in Paris, Wuhan, and Philadelphia. Lead sponsors running encephalitis studies include Tongji Hospital, Hospices Civils de Lyon, and Assistance Publique - Hôpitaux de Paris.

Browse encephalitis trials by phase

About Encephalitis Clinical Trials

Looking for clinical trials for Encephalitis? There are currently 6 studies actively recruiting participants. Clinical trials offer access to new treatments before they are widely available, and every approved therapy in use today was first tested through a clinical trial.

Below you can browse trials, sign up for alerts when new Encephalitis trials open, and view eligibility criteria for each study. Each listing includes the study phase, locations, and enrollment details.

Frequently Asked Questions

Common questions about Encephalitis clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 120 of 48 trials

Recruiting
Phase 2

Cytotoxic T Lymphocytes in Treating Patients With Malignancies With BK and/or JC Virus

Merkel Cell CarcinomaMalignant NeoplasmAcquired Immunodeficiency Syndrome+5 more
M.D. Anderson Cancer Center100 enrolled1 locationNCT02479698
Recruiting
Phase 3

Dexamethasone in Tick-borne Encephalitis

Tick Borne Encephalitis
University Medical Centre Ljubljana200 enrolled1 locationNCT07584525
Recruiting
Phase 1

Safety and Pharmacodynamics of QH103 Cell Injection in the Treatment of Patients With Relapsed/Refractory Antibody-Mediated Neurological Autoimmune Diseases.

Neuromyelitis Optica Spectrum Disorder (NMOSD)Multiple Sclerosis (MS)Myasthenia Gravis (MG)+4 more
Tongji Hospital6 enrolled1 locationNCT07526493
Recruiting
Early Phase 1

CD19/BCMA-Targeted UCAR-T for Patients With Neurological Autoimmune Diseases

Relapsing or Refractory Multiple Sclerosis (MS)Myasthenia Gravis (MG)Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)+1 more
Tongji Hospital36 enrolled1 locationNCT07337785
Recruiting
Phase 2

A Study in Participants With Anti-NMDAR Encephalitis and Anti-NMDAR Autoantibody-Associated Psychiatric Disease

Autoimmune EncephalitisAnti-N-methyl-D-aspartate Receptor (NMDAR) Encephalitis (ANRE)Anti-N-methyl-D-aspartate Receptor (NMDAR) Antibody-associated Psychiatric Disease
Arialys Australia Pty Ltd30 enrolled1 locationNCT07093333
Recruiting
Phase 2

Is [18F]-DPA-714 PET a Good Marker of Neuroinflammation in Autoimmune Encephalitis?

Autoimmune Encephalitis (AE)
University Hospital, Toulouse40 enrolled1 locationNCT07488117
Recruiting
Phase 3

A Study to Evaluate the Efficacy, Safety, Pharmacokinetics (PK), and Pharmacodynamics (PD) of Satralizumab in Participants With Anti-N-methyl-D-aspartic Acid Receptor (NMDAR) or Anti-leucine-rich Glioma-inactivated 1 (LGI1) Encephalitis

NMDAR Autoimmune EncephalitisLGI1 Autoimmune Encephalitis
Hoffmann-La Roche152 enrolled93 locationsNCT05503264
Recruiting
Not Applicable

High-throughput Omic Technology for Identification of Biomarkers of Relapsing Acute Disseminated Encephalomyelitis in Immune Cell Network

Acute Disseminated EncephalomyelitisEncephalitis Autoimmune
University Hospital, Angers20 enrolled8 locationsNCT06863974
Recruiting

FDG-PET in the Diagnosis of Autoimmune Encephalitis

Autoimmune Encephalitis
University of Milano Bicocca90 enrolled6 locationsNCT06019975
Recruiting

Study of Pathogenic Mechanisms and Identification of Novel Autoantibodies in Autoimmune Encephalitis

Autoimmune Encephalitis
Fondazione Policlinico Universitario Agostino Gemelli IRCCS20 enrolled1 locationNCT07477015
Recruiting

Long-term Impact of NMDAR Encephalitis, Level 3

NMDAR Autoimmune Encephalitis
Hospices Civils de Lyon30 enrolled1 locationNCT07158229
Recruiting

CoMind Early Feasibility Study

EncephalitisTraumatic Brain InjuryStroke+6 more
CoMind Technologies Limited581 enrolled14 locationsNCT06368648
Recruiting

Unhide® Project: A Digital Health Platform to Collect Lifestyle Data for Brain Inflammation Research

Traumatic Brain InjuryEhlers-Danlos SyndromePost-Acute COVID-19 Syndrome+41 more
Brain Inflammation Collaborative10,000 enrolled1 locationNCT04806620
Recruiting

Risk Assessment of Community Spread of Multiple Endemic Infectious Diseases in a One Health Perspective

Streptococcus PneumoniaeMalariaMeningitis+55 more
Institut Pasteur du Cambodge10,000 enrolled1 locationNCT07358910
Recruiting

Optic Nerve Ultrasound for Assessing Cerebral Inflammation and Intracranial Hypertension in Cerebral Pathologies

UltrasoundStrokeMeningitis/Encephalitis+3 more
Spitalul Clinic de Boli Infecțioase și tropicale "Dr. Victor Babeș"200 enrolled2 locationsNCT07332234
Recruiting
Phase 1Phase 2

A Study to Assess the Safety, Reactogenicity, and Immunogenicity of SK Japanese Encephalitis Messenger Ribonucleic Acid (mRNA) Vaccines (GBP560) in Healthy Adults

Japanese Encephalitis Virus Disease
SK Bioscience Co., Ltd.402 enrolled3 locationsNCT06680128
Recruiting
Early Phase 1

Universal Chimeric Antigen Receptor T-Cell (UCAR T-cell) Therapy Targeting CD19/B Cell Maturation Antigen (CD19/BCMA) in Patients With r/r Neurological Autoimmune Diseases

Myasthenia GravisAutoimmune EncephalitisMultiple Sclerosis+2 more
Tianjin Huanhu Hospital12 enrolled1 locationNCT06939166
Recruiting

Burden of Tick-borne Encephalitis and Cost-effectiveness of Vaccination in the Czech Republic

Tick-borne Encephalitis (TBE)
Charles University, Czech Republic209 enrolled4 locationsNCT07274046
Recruiting

Acute Infectious Encephalitis and Myelitis in Guadeloupe by New Generation Sequencing

Acute EncephalitisAcute Myelitis
Centre Hospitalier Universitaire de la Guadeloupe100 enrolled1 locationNCT07251049
Recruiting

Evaluation of Knowledge on Tick-borne Encephalitis Virus (TBEV) Infection Among General Practitioners in France

Tick-borne Encephalitis, France
University Hospital, Strasbourg, France100 enrolled1 locationNCT07191223